tus insignias Rango 52S $12–$21 0% of range Calificación del Analista SELL 7 analysts Precio Objetivo $12 +1% upside P/E -176.4 ROE -6.0% Margen de Beneficio Neto -14.6%

AMRN Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

03
Precio $12.35
Capitalización Bursátil (MRQ) $5.19B
P/E (TTM) -176.4
BPA (TTM) $-0.07
Ingresos (TTM) $186M
ROE (TTM) -6.0%
Rango 52S $12–$21

AMRN Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

04
rango
barras

La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.

Divisiones de acciones 3
Fecha ex-dividendo División Tipo
11 de abril de 2025 1-for-20 Inversa
18 de enero de 2008 1-for-10 Inversa
19 de octubre de 1998 1-for-10 Inversa

Acerca de Amarin Corporation plc - American Depositary Shares Descripción general de la empresa de Wikipedia

05 · wikidata

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.

History

Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.

In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.

Products and development

Vascepa (USA) / Vazkepa (EU)

Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.

Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.

HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.

On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.

Patent disputes

On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.

== Finance ==

Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗

Wikidata ↗

sectorHealthcare industriaBiotechnology empleados80 paísIE

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

06
Ingresos$214M
2016-12-31 → 2025-12-31
BPA$-0.09
2016-12-31 → 2025-12-31
Flujo de caja libre·
2016-12-31 → 2020-12-31
Margen neto-14.6%
2016-12-31 → 2025-12-31
Valoración y ratios 07–12

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica Tendencia a 5 años AMRN promedio 5A Mediana de Pares Veredicto
P/E (TTM) -176.4promedio 5A ≈591.4 ≈591.4 · ·
P/S (TTM) 27.9promedio 5A ≈22.7 ≈22.7 · ·
P/C (MRQ) 11.7promedio 5A ≈11.3 ≈11.3 · ·
Price / Cash Flow (Precio / Flujo de Caja) 764.0promedio 5A ≈589.2 ≈589.2 · ·
Precio / Valor Contable Tangible (MRQ) 12.0promedio 5A ≈18.7 ≈18.7 · ·

La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.

valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

14
Sorpresa Media 49.9%
Próximo informe Oct 27, 2026
PeríodoInformeEPS ActualEPS est.Sorpresa
30 de junio de 2026 Jul 28, 2026 $-0.02 $-0.01 -96.1%
31 de marzo de 2026 $-0.09 $0.09 -203.8%
31 de diciembre de 2025 $0.01 $0.00 —
30 de septiembre de 2025 $0.08 $-0.58 113.8%
30 de junio de 2025 $0.66 $-0.18 466.3%
31 de marzo de 2025 $-0.76 $-0.58 -30.7%

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

15
Estado de resultados 18
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Cost of Revenue ····$121M$131M$96M$55M$45M$34M$28M$20M
Gross Profit $121M$81M$166M$242M$462M$483M$334M$175M$136M$96M$54M$34M
R&D Expense $20M$21M$22M$30M$29M$39M$34M$56M$47M$50M$51M$50M
SG&A Expense $115M$152M$200M$304M$408M$463M$324M$227M$135M$111M$101M$79M
Operating Expenses $171M$173M$233M$348M$451M$502M$358M$283M$182M$161M$152M$130M
Operating Income $-50M$-92M$-68M$-106M$11M$-20M$-24M$-108M$-46M$-66M$-98M$-96M
Interest Expense $7.0K$7.0K$8.0K$15.0K$129.0K$3M$7M$9M$10M$19M$20M$19M
Interest Income $11M$13M$12M$3M$1M$5M$8M$1M$429.0K$234.0K$132.0K$96.0K
Other Non-op $3M$1M$2M$-740.0K$-302.0K$104.0K$-75.0K$-326.0K$74.0K$-482.0K$-228.0K$4M
Pretax Income $-36M$-77M$-54M$-104M$11M$-17M$-22M$-116M$-55M$-76M$-118M$-59M
Income Tax $3M$5M$5M$2M$4M$745.0K$164.0K$96.0K$13M$10M$-3M$-3M
Net Income $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
EPS (Basic) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.32
EPS (Diluted) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Shares (Basic) 414,984,000410,937,000407,655,000401,155,000395,992,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,719,000
Shares (Diluted) 414,984,000410,937,000407,655,000401,155,000402,480,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,824,000
EBITDA $-50M$-92M$-68M··$-20M·$-108M$-46M$-66M$-98M$-96M
Balance general 27
Métrica Tendencia 202520242023202220212020201920182017201620152014
Cash & Equivalents $135M$121M$199M$218M$219M$187M$645M$249M$74M$98M$107M$120M
Short-term Investments $168M$173M$121M$92M$235M$314M······
Receivables $127M$122M$134M$131M$164M$155M$116M$67M$45M$20M$14M$8M
Inventory $196M$166M$259M$229M$235M$189M$77M$58M$30M$21M$19M$14M
Prepaid Expense $24M$13M$12M$19M$22M$31M$13M$3M$3M$7M$3M$3M
Other Current Assets ···········$3M
Current Assets $650M$595M$725M$689M$879M$879M$855M$378M$153M$146M$144M$145M
PP&E (Net) $12.0K$16.0K$114.0K$874.0K$1M$2M$2M$63.0K$28.0K$78.0K$243.0K$381.0K
PP&E (Gross) $1M$1M$1M$3M$3M$4M$3M$902.0K$844.0K$821.0K$997.0K$969.0K
Accum. Depreciation $1M$1M$1M$2M$2M$2M$1M$839.0K$816.0K$755.0K$754.0K$588.0K
Intangibles $13M$16M$19M$22M$24M$14M$15M$7M$8M$9M$9M$10M
Other Non-current Assets $1M$1M$1M$458.0K$456.0K$432.0K$1M$174.0K$174.0K$741.0K$174.0K$3M
Total Assets $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Accounts Payable $45M$40M$53M$65M$115M$106M$50M$38M$25M$6M$11M$9M
Current Liabilities $194M$180M$259M$259M$371M$307M$242M$157M$109M$76M$51M$40M
Capital Leases $6M$8M$9M$10M$9M$9M$9M·····
Other Non-current Liabilities $11M$12M$9M$8M$8M$6M$4M$11M$1M$710.0K$335.0K$386.0K
Total Liabilities $211M$199M$280M$291M$401M$339M$274M$233M$227M$176M$301M$260M
Long-term Debt ······$50M$80M$92M$94M$92M$105M
Total Debt ·····$0·$80M$93M$101M$106M$105M
Common Stock $310M$305M$303M$299M$294M$290M$269M$247M$209M$207M$150M$143M
Paid-in Capital $1.92B$1.91B$1.90B$1.89B$1.86B$1.82B$1.76B$1.28B$978M···
Retained Earnings $-1.71B$-1.67B$-1.59B$-1.53B$-1.42B$-1.43B$-1.41B$-1.39B$-1.27B$-1.20B$-1.12B$-970M
Treasury Stock $67M$65M$64M$62M$61M$51M$36M$10M$4M$1M$411.0K$217.0K
Stockholders' Equity $459M$486M$552M$595M$667M$628M$608M$152M$-65M$-9M$-129M$-88M
Liabilities + Equity $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Shares Outstanding 416,214,102411,584,851408,824,093408,824,093396,598,008392,538,081360,103,901325,850,013271,022,011269,363,696183,403,263174,590,372
Flujo de Efectivo 17
Métrica Tendencia 202520242023202220212020201920182017201620152014
D&A ·······$23.0K$62.0K$138.0K$166.0K$198.0K
Stock-based Comp $14M$18M$16M$26M$37M$46M$31M$19M$14M$14M$14M$9M
Deferred Tax ········$11M$9M$-4M$-4M
Amort. of Intangibles $3M$3M$3M$3M$2M$1M$679.0K$646.0K$646.0K$645.0K$646.0K$646.0K
Restructuring $36M$0$11M$14M$14M·······
Operating Cash Flow $7M$-31M$7M$-180M$-67M$-22M$-9M$-95M$-33M$-72M$-84M$-75M
CapEx ·····$252.0K$2M$58.0K$12.0K$21.0K$28.0K·
Investing Cash Flow $9M$-46M$-26M$175M$104M$-377M$-2M$-58.0K$-12.0K$-21.0K··
Net Debt Issued ·····$-50M·$-15M$-3M···
Stock Issued ······$440M$265M·$65M··
Stock Repurchased ··········$194.0K·
Net Stock Activity ·······$265M·$65M$-194.0K·
Financing Cash Flow $-2M$-1M$230.0K$-379.0K$-5M$-59M$410M$271M$8M$63M··
Net Change in Cash $14M$-78M$-18M$-5M$32M$-458M$398M$176M$-25M$-9M$-13M$-72M
Taxes Paid $1M$4M$2M$-2M$4M$-207.0K$-67.0K·····
Free Cash Flow ·····$-22M·$-95M$-33M$-72M$-85M·
Levered FCF ·····$-25M·$-104M$-45M$-93M$-104M·
Rentabilidad 8
Métrica Tendencia 202520242023202220212020201920182017201620152014
Gross Margin 56.6%35.6%53.9%··78.6%·76.2%75.2%73.6%65.9%62.2%
Operating Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
Net Margin -18.2%-35.9%-19.3%··-2.9%·-50.8%-37.5%-66.4%-140.9%-104.0%
Pretax Margin -16.9%-33.8%-17.5%··-2.8%·-50.8%-30.3%-58.7%-144.7%-109.2%
EBITDA Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
ROA -5.7%-10.8%-6.9%··-1.9%·-42.5%-41.3%-50.8%-66.9%-26.6%
ROE -8.4%-16.2%-10.7%··-2.9%·-234.1%183.0%124.9%105.9%92.2%
ROIC -11.8%-20.1%-13.5%··-3.3%·-46.6%-200.8%-80.6%417.0%-551.6%
Liquidez y Solvencia 5
Métrica Tendencia 202520242023202220212020201920182017201620152014
Current Ratio 3.33.32.8··2.9·2.41.41.92.83.6
Quick Ratio 2.22.31.8··2.1·2.01.11.62.43.2
Debt / Equity ·····0.0·0.5-1.4-11.2-0.8-1.2
LT Debt / Equity ·······0.3-1.1-9.4-0.7-1.0
Interest Coverage -7167.1-13113.9-8448.5··-7.5·-12.2-4.7-3.5-4.9-5.2
Eficiencia 3
Métrica Tendencia 202520242023202220212020201920182017201620152014
Asset Turnover 0.30.30.4··0.7·0.81.10.80.50.3
Inventory Turnover ·····1.0·1.21.81.71.71.2
Receivables Turnover 1.71.82.3··4.5·4.15.57.77.59.4
Por Acción 5
Métrica Tendencia 202520242023202220212020201920182017201620152014
Book Value / Share $1.10$1.18$1.35··$1.60·$0.47$-0.24$-0.03$-0.70$-0.51
Revenue / Share $0.51$0.56$0.75··$1.61·$0.77$0.67$0.61$0.45$0.31
Cash Flow / Share $0.02$-0.08$0.02··$-0.06·$-0.32$-0.12$-0.34$-0.47$-0.42
Cash / Share $0.32$0.29$0.49··$0.48·$0.76$0.27$0.36$0.58$0.68
EPS (TTM) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Tasas de Crecimiento 3
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue YoY -6.6%-25.5%-16.9%-36.7%-5.0%·······
Revenue CAGR 3Y -16.7%-26.8%-20.6%·········
Revenue CAGR 5Y -19.0%···········
Valoración (TTM) 14
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue TTM $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Net Income TTM $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
Market Cap $5.81B$4.03B$7.11B··$38.39B·$88.70B$21.74B$16.59B$6.93B$3.42B
Enterprise Value ·····$37.89B·$88.53B$21.76B$16.60B$6.93B$3.41B
P/E -155.1-49.0-116.0-93.13370.0-1956.0-6125.7-697.9-320.8-150.2-45.5-54.4
P/S 27.217.623.2··62.5·387.0120.0127.684.863.1
P/B 12.78.312.9··61.2·582.3-333.9-1831.8-53.7-38.7
P / Tangible Book 13.08.613.417.141.562.6······
P / Cash Flow 863.6-130.01033.9··-1765.4·-936.6-661.9-231.0-81.8-47.3
P / FCF ·····-1745.2·-936.0-661.7-231.0-81.8·
EV / EBITDA ·····-1927.7·-818.0-477.6-252.9-70.6-35.5
EV / FCF ·····-1722.4·-934.2-662.3-231.0-81.8·
EV / Revenue ·····61.7·386.2120.1127.684.862.9
Earnings Yield -0.64%-2.0%-0.86%-1.1%0.03%-0.05%-0.02%-0.14%-0.31%-0.67%-2.2%-1.8%

Período más reciente a la izquierda · valores nulos mostrados como ·

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

16
Métrica 2025-12-312024-12-312023-12-312022-12-312021-12-31
Ingresos $214M $229M $307M $369M $583M
Margen Bruto % 56.6% 35.6% 53.9% · ·
Margen Operativo % -23.5% -40.2% -22.0% · ·
Beneficio neto $-39M $-82M $-59M $-106M $8M
EPS Diluido $-0.09 $-0.20 $-0.15 $-0.26 $0.02

Propietarios institucionales (13F) 88 declarantes · $64.3M total · A fecha de 30 de junio de 2026

17

Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.

Tenedores 88
Valor en tenencia $64.3M
Nuevas posiciones 21
Posiciones cerradas 7
Actividad institucional — Q2 2026 vs trimestre anterior
Nuevas posiciones Posiciones cerradas Aumentado Disminuido Cambio neto de acciones
21 (+13 vs trimestre anterior) 7 (-12 vs trimestre anterior) 16 (-3 vs trimestre anterior) 14 (-1 vs trimestre anterior) +79K

Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.

Institución Valor Acciones % de 13F rastreadas Tipo
Sarissa Capital Management LP $26 673 916 1 673 395 41,49% Acciones
Kynam Capital Management, LP $8 495 733 532 982 13,22% Acciones
MORGAN STANLEY $3 564 456 223 617 5,54% Acciones
Waterfront Wealth Inc. $3 183 561 213 949 4,95% Acciones
Brooklands Fund Management Ltd $2 741 449 177 325 4,26% Acciones
Eversept Partners, LP $2 316 018 145 296 3,60% Acciones
MILLENNIUM MANAGEMENT LLC $1 845 980 115 808 2,87% Acciones
TWO SIGMA INVESTMENTS, LP $1 602 145 100 511 2,49% Acciones
CITADEL ADVISORS LLC $1 520 103 95 364 2,36% Acciones
BNP PARIBAS FINANCIAL MARKETS $1 144 699 71 813 1,78% Acciones
LCM Capital Management Inc $818 710 51 362 1,27% Acciones
RENAISSANCE TECHNOLOGIES LLC $771 002 48 369 1,20% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $765 120 48 000 1,19% Opción de compra
JANE STREET GROUP, LLC $599 790 37 628 0,93% Acciones
George Kaiser Family Foundation $593 080 37 207 0,92% Acciones
TWO SIGMA ADVISERS, LP $516 265 36 995 0,80% Acciones
SEI INVESTMENTS CO $465 628 29 211 0,72% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $462 276 29 001 0,72% Acciones
STATE STREET CORP $398 755 25 016 0,62% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $385 748 24 200 0,60% Opción de venta
Bleakley Financial Group, LLC $374 670 23 505 0,58% Acciones
AMERIPRISE FINANCIAL INC $302 573 18 982 0,47% Acciones
State of New Jersey Common Pension Fund D $300 931 18 879 0,47% Acciones
CITADEL ADVISORS LLC $299 672 18 800 0,47% Opción de venta
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS $292 818 18 370 0,46% Acciones
RAYMOND JAMES FINANCIAL INC $289 550 18 165 0,45% Acciones
R Squared Ltd $269 992 16 938 0,42% Acciones
State of Tennessee, Department of Treasury $239 164 15 004 0,37% Acciones
Quadrature Capital Ltd $236 581 14 842 0,37% Acciones
Quinn Opportunity Partners LLC $228 022 14 305 0,35% Acciones
Cubist Systematic Strategies, LLC $224 390 13 699 0,35% Acciones
WELLS FARGO & COMPANY/MN $221 773 13 913 0,34% Acciones
EntryPoint Capital, LLC $194 882 12 226 0,30% Acciones
Jump Financial, LLC $191 407 12 008 0,30% Acciones
GEODE CAPITAL MANAGEMENT, LLC $187 629 11 771 0,29% Acciones
OSAIC HOLDINGS, INC. $184 333 11 565 0,29% Acciones
NJ State Employees Deferred Compensation Plan $178 542 10 900 0,28% Acciones
Verdad Advisers, LP $166 270 10 431 0,26% Acciones
CITADEL ADVISORS LLC $164 182 10 300 0,26% Opción de compra
UBS Group AG $160 404 10 063 0,25% Acciones
Steward Partners Investment Advisory, LLC $142 025 8 910 0,22% Acciones
NEW YORK STATE COMMON RETIREMENT FUND $121 224 7 605 0,19% Acciones
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO $92 038 5 774 0,14% Acciones
Federation des caisses Desjardins du Quebec $73 518 4 615 0,11% Acciones
RHUMBLINE ADVISERS $59 498 3 733 0,09% Acciones
NATIONAL BANK OF CANADA /FI/ $40 137 2 518 0,06% Acciones
ROYAL BANK OF CANADA $30 000 1 877 0,05% Acciones
GAMMA Investing LLC $25 121 1 576 0,04% Acciones
NewEdge Advisors, LLC $21 471 1 347 0,03% Acciones
Farther Finance Advisors, LLC $15 271 958 0,02% Acciones

Mostrar todos los 88 propietarios institucionales →

Activistas y propietarios del %+ 5 35 tenencias

18

Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.

Declarante Presentado Participación Estado Propósito Presentación
Alexander J Denner, Sarissa Capital Management LP 27 de agosto de 2026 6,09% Enmienda · SEC
Sarissa Capital Management LP, Alexander J Denner ×3 presentaciones 25 de marzo de 2025 8,08% Enmienda Campaña de la junta directiva SEC
28 de febrero de 2023 · Presentación inicial · SEC
27 de febrero de 2023 · Presentación inicial · SEC
21 de febrero de 2023 · Presentación inicial · SEC
OR ×6 presentaciones 15 de febrero de 2023 · Presentación inicial · SEC
14 de febrero de 2023 · Presentación inicial · SEC
10 de febrero de 2023 · Presentación inicial · SEC
19 de enero de 2023 · Presentación inicial · SEC
16 de junio de 2022 · Presentación inicial · SEC
Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 presentaciones 23 de agosto de 2013 · Presentación inicial Inversión pasiva SEC
Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 presentaciones 22 de julio de 2013 · Presentación inicial Campaña de la junta directiva SEC
Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 presentaciones 24 de agosto de 2011 · Presentación inicial · SEC
OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 presentaciones 28 de abril de 2011 · Presentación inicial · SEC
Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 presentaciones 10 de diciembre de 2010 · Presentación inicial · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Informantes de la empresa 43 insiders · 18 directivos · 27 consejeros

19
Insider Rol Última actividad Acciones en propiedad Compras 12m Ventas 12m Neto 12m
Aaron Berg President and CEO 26 de junio de 2026 M 85 648 0 0 $0
Patrick Holt President and CEO 22 de enero de 2024 P 314 426 0 0 $0
Karim Mikhail President and CEO 21 de febrero de 2023 A 283 507 0 0 $0
John F Thero President and CEO 30 de julio de 2021 M 3 252 752 0 0 $0
Peter L. Fishman SVP, CFO 1 de agosto de 2026 A 7 619 0 0 $0
Thomas Charles Reilly EVP and CFO 1 de julio de 2024 M 94 305 0 0 $0
Michael Wayne Kalb SVP and CFO 29 de julio de 2022 M 337 314 0 0 $0
David Paul Keenan EVP, Chief Operating Officer 1 de julio de 2026 A 13 470 0 0 $0
Jonathan Provoost EVP, Chief Legal Officer 1 de julio de 2026 A 4 624 0 0 $0
Steven B Ketchum EVP, Chief Scientific Officer 1 de julio de 2026 A 42 680 0 0 $0
Jason M. Marks EVP,Chief Global Legal Officer 19 de agosto de 2022 M 21 917 0 0 $0
Joseph T Kennedy General Counsel 30 de julio de 2021 M 317 860 0 0 $0
Mark Salyer Chief Commercial Officer 1 de febrero de 2018 A · 0 0 $0
Michael James Farrell VP, Finance 1 de febrero de 2016 A 30 190 0 0 $0
Paul Huff Chief Commercial Officer 26 de julio de 2012 A 0 0 0 $0
Stuart D Sedlack Senior Vice President 26 de julio de 2012 A 0 0 0 $0
Paresh Soni SVP and Head of Development 1 de febrero de 2012 A 0 0 0 $0
Frederick W Ahlholm Vice President Finance 1 de febrero de 2012 A 0 0 0 $0
Oliver O'Connor Consejero 18 de abril de 2026 M 801 0 0 $0
Paul Cohen Consejero 18 de abril de 2026 M 836 0 0 $0
Diane E. Sullivan Consejero 18 de abril de 2026 M 836 0 0 $0
Louis Sterling III Consejero 18 de abril de 2026 M 4 049 0 0 $0
Patrice Eadon Bonfiglio Consejero 18 de abril de 2026 M 836 0 0 $0
Keith Horn Consejero 18 de abril de 2026 M 836 0 0 $0
Odysseas D Kostas Consejero 18 de abril de 2026 M 836 0 0 $0
Mark Dipaolo Consejero 18 de abril de 2025 M 401 0 0 $0
Olsen Per Wold Consejero 10 de enero de 2023 M 171 027 0 0 $0
Murray Stewart Consejero 9 de enero de 2023 A · 0 0 $0
Adam Mark Berger Consejero 20 de octubre de 2022 A · 0 0 $0
Geraldine Murphy Consejero 20 de octubre de 2022 A · 0 0 $0
Alfonso G Zulueta Consejero 27 de junio de 2022 A · 0 0 $0
Erin S. Enright Consejero 27 de junio de 2022 A · 0 0 $0
Kristine Peterson Consejero 27 de junio de 2022 A 0 0 0 $0
Patrick J O'Sullivan Consejero 27 de junio de 2022 A · 0 0 $0
Lars Ekman Consejero 27 de junio de 2022 A 0 0 0 $0
VAN HEEK G JAN Consejero 27 de junio de 2022 A 14 168 0 0 $0
Joseph S Zakrzewski Consejero 15 de diciembre de 2021 P 196 547 0 0 $0
David M Stack Consejero 14 de junio de 2021 A 40 000 0 0 $0
Dr. James I. Healy Consejero 11 de julio de 2016 A 90 000 0 0 $0
GORDON CARL L Consejero 4 de septiembre de 2012 S 5 700 0 0 $0
Joseph Anderson Consejero 10 de julio de 2012 A 11 683 0 0 $0
David W Feigal Jr Consejero 12 de julio de 2011 A · 0 0 $0
Abingworth LLP Propietario del 10% 19 de abril de 2012 S 1 599 168 0 0 $0

Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto

AMRN Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

21
calificación · 7 analistas VENTA
Objetivo mediano $12.50 +1,2%
0 0,0% Compra fuerte
0 0,0% Compra
2 28,6% Mantener
3 42,9% Venta
2 28,6% Venta fuerte

Precio objetivo a 12 meses

2 analistas · 2026-10-03

Objetivo medio $12.50 +1,2%

Ahora Precio Actual $12.35
Mín$12.00 Media$12.50 Máx$13.00

Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector

22

Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
AMRN $5.81B -155.1 -6.6% -18.2% -8.4% 56.6%
ALKS $4.63B 19.6 -5.2% 16.4% 14.0% ·
PRTA $514M -2.1 -92.8% -2520.6% -63.6% ·

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

26

Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.

Tu selección se guarda y te sigue en todos los tickers.

Fuente: SEC 10-Q presentada el Jul 29, 2026